RF & HIFEM for
What is EMSCULPT NEO
EMSCULPT NEO is the only non-invasive technology that simultaneously uses radiofrequency and HIFEM+ (High-intensity focused electromagnetic energy) to eliminate fat and build muscle.
The end result is more fat reduction and muscle growth in less time than with any single gold-standard product.
2 THERAPIES IN A SINGLE PROCEDURE
Combination of synchronized RF and HIFEM+ causes dual effect in the tissues
UP TO 9 TREATABLE BODY AREAS
Thanks to the 3 different types of applicators EMSCULPT NEO can treat most problematic body parts
The procedure runs independently once applicators are affixed
How does EMSCULPT NEO work?
EMSCULPT NEO is a completely non-invasive body-shaping treatment which does not require surgery, needles or anesthesia.
It is based on an applicator simultaneously emitting synchronized RF and HIFEM+ energies.
The muscle temperature raises by several degrees, similar to what a warm-up activity does before any workout.
Muscles in the treated area are intensely contracted.
Shortly after therapy starts the temperature in fat cells reaches levels that cause their permanent damage.
The fat cells are slowly removed from the body and the strained muscle fibers initiate a growth process. This results in fat elimination and muscle building.
Activation of Skeletal Muscle Satellite Cells by a Device Simultaneously Applying High Intensity Focused Electromagnetic Technology and Novel RF Technology
Halaas Y.; Duncan D.; Bernardy J.;
Ondrackova P.; Dinev I. (2019)
Deletion of adipocytes induced by a novel device simultaneously delivering synchronized radiofrequency and hifem:
Human histological study
Goldberg D. (2020)
A Novel Technology Combining RF and Magnetic Fields: Technical Elaboration on Novel RF Electrode Design
Duncan D. (2020)
Listen to your peers
David J. Goldberg, M.D., Bruce E. Katz M.D.: “Not until EMSCULPT NEO have we ever had a single device that both gets rid of fat through apoptosis and tightens muscle. (…) It´s one less machine in the office.”
Yael Halaas, M.D., Richard Goldfarb, M.D.: “This for me is a tremendous investment for both my patients and (…) for my colleagues as well. (…) Patients really are seeing a response.”
Brian M. Kinney, M.D., Melanie D. Palm, M.D.: “In the original study we had patients usually below 30, on average about 25 BMI. (…) Taking it up to 35 gives another category of patients an opportunity.”